Cellectis SA (CLLS) has released an update.
Cellectis SA, a biotech company specializing in gene-editing therapies, has been granted an Orphan Drug Designation by the European Commission for UCART22, a CAR T-cell product candidate for Acute Lymphoblastic Leukemia (ALL). UCART22 shows promise with a 67% preliminary response rate in clinical trials, offering hope for relapsed/refractory ALL patients with limited treatment options. The designation will provide various incentives to Cellectis, aiming to bring this potential new treatment to market for a rare and rapidly progressing leukemia.
For further insights into CLLS stock, check out TipRanks’ Stock Analysis page.
